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Abstract
Background: The REversion-inducing Cysteine-rich protein with Kazal motif (RECK) is a well-known inhibitor of
matrix metalloproteinases (MMPs) and cellular invasion. Although high expression levels of RECK have already been
correlated with a better clinical outcome for several tumor types, its main function, as well as its potential
prognostic value for breast cancer patients, remain unclear.
Methods: The RECK expression profile was investigated in a panel of human breast cell lines with distinct
aggressiveness potential. RECK functional analysis was undertaken using RNA interference methodology. RECK
protein levels were also analyzed in 1040 cases of breast cancer using immunohistochemistry and tissue
microarrays (TMAs). The association between RECK expression and different clinico-pathological parameters, as well
as the overall (OS) and disease-free (DFS) survival rates, were evaluated.
Results: Higher RECK protein expression levels were detected in more aggressive breast cancer cell lines (T4-2,
MDA-MB-231 and Hs578T) than in non-invasive (MCF-7 and T47D) and non-tumorigenic (S1) cell lines. Indeed,
silencing RECK in MDA-MB-231 cells resulted in elevated levels of pro-MMP-9 and increased invasion compared with
scrambled (control) cells, without any effect on cell proliferation. Surprisingly, by RECK immunoreactivity analysis on
TMAs, we found no association between RECK positivity and survival (OS and DFS) in breast cancer patients. Even
considering the different tumor subtypes (luminal A, luminal B, Her2 type and basal-like) or lymph node status, RECK
remained ineffective for predicting the disease outcome. Moreover, by multivariate Cox regression analysis, we
found that RECK has no prognostic impact for OS and DFS, relative to standard clinical variables.
Conclusions: Although it continues to serve as an invasion and MMP inhibitor in breast cancer, RECK expression
analysis is not useful for prognosis of these patients.
Keywords: RECK, Breast cancer, Immunohistochemistry, Tissue microarray, Biomarker
Background
Breast cancer is the first in incidence and the second in
mortality among women [1]. Currently, a reduction in
overall cancer death rates is due to a combination of earl-
ier diagnosis and treatment improvement [1]. Neverthe-
less, breast cancer remains a worldwide health problem.
The lack of more informative biomarkers to discriminate
among patients according to the prognosis and clinical
course complicates the choice of therapeutic strategy.
Metastasis development is the main death factor at-
tributed to breast cancer [2]. The organized breakdown
of the extracellular matrix (ECM) by matrix metallopro-
teinases (MMPs) is an essential event in the complex
metastatic cascade [3]. Inhibitors of MMPs, known as
tissue inhibitors of MMPs (TIMPs), and the membrane-
associated MMP inhibitor RECK are also critical for
controlling the maintenance of the ECM integrity due to
their regulation of MMP function [4–7].
Elevated MMP expression and activity levels have been
associated with poor prognosis in several cancer types
[8–10]. Surprisingly, a higher expression of MMP inhibi-
tors, such as TIMPs, correlates with a worse outcome
for breast cancer patients [11–14]. This ambiguous
nature of TIMPs may be due to the wide variety of
TIMP functions, which are independent of their activities
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as MMP inhibitors [6]. However, this finding remains
unclear.
RECK, another type of MMP inhibitor, has been
shown to decrease cellular invasion [15], most likely by
inhibiting the enzymatic activity of MMP-2, MMP-9 and
MMP-14 [16, 17]. Additionally, RECK has been shown
to decrease MMP-9 mRNA levels [18]. The potential
prognostic power of RECK has already been reported for
other tumors, such as pancreatic, liver, lung and colorec-
tal cancers [19–23], where RECK expression is inversely
correlated with MMP expression during tumor progres-
sion [23]. Thus, high expression levels of RECK correlate
with a better clinical outcome [23].
However, in breast cancer, the RECK expression profile
is controversial and remains unclear [24–27]. Moreover,
no functional analysis in human mammary tumors has
been previously reported. A retrospective study using
119 cases of breast cancer samples, suggests, similar to
other cancer types, that a low expression of RECK indi-
cates a shorter survival rate for patients with invasive
breast cancer [24]. The available data indicated that
lower RECK mRNA levels were expressed in tumor tis-
sue samples than in normal breast tissue samples, and
higher levels were found in invasive human breast can-
cer cells than in less aggressive ones [24–26].
In the present study, we aimed to evaluate the prognos-
tic significance of RECK in breast cancer patient outcome.
The RECK protein expression levels were analyzed in a
large series (1040) of breast cancer cases using immuno-
histochemistry of tissue microarrays (TMAs). Further-
more, we investigated RECK function in mammary
neoplasia using RECK-silenced human breast cancer cells,
obtained by RNA interference methodology. Here, we
present evidence supporting that, although RECK acts as
a negative regulator of MMP-9 and invasion, its levels of
expression fail to correlate with patient survival rates.
Methods
Patients and methods
All breast samples were obtained from patients diag-
nosed and treated at the A. C. Camargo Hospital, São
Paulo, Brazil. TMAs were arranged from a series of 1040
cases of primary breast carcinoma from patients diag-
nosed between 1980 and 1999. Duplicate 1 mm cores
from tumors were used in the TMAs. The median age of
the patients was 55 years (range: 26–90 years). The tumor
tissues were removed at surgery. The A. C. Camargo Hos-
pital Ethics Committee approved this research (Process
number: 1648/12) and waived the need for informed con-
sent term.
Vimentin and pan-cytokeratin were used as tissue im-
munoreactivity and staining controls. RECK staining was
performed using a monoclonal antibody diluted 1:200
(Cell Signaling, Beverly, MA, USA). Several patient and
tumor characteristic data were available, including age,
menopausal status, tumor size, lymph node stage, SBR
stage (Scarff-Bloom-Richardson, histological classifica-
tion method) and TNM tumor stage. The expression
state of several biomarkers, such as estrogen receptor
(ER), progesterone (PR), Her-2 and cytokeratins (CK5,
CK6, CK8, CK14 and CK18), was also evaluated by two
distinct pathologists.
The ScanScope XT device was used for slide scanning.
The percentage of cells positively stained for RECK, and
its staining pattern in the TMA core, was determined
using the Spectrum Plus computational program, by a
trained person. For each subject, at least three measure-
ments were obtained, from two distinct slides, with sam-
ples represented in duplicate. The average of these three
values was considered as the RECK immunoreactivity
for each subject. RECK immunoreactivity values greater
than the median were considered as positive (or high
expression).
Cell lines and reagents
Six breast cell lines (S1, MCF-7, T47D, T4-2, MDA-
MB-231 and Hs578T) with distinct tumorigenic and
aggressiveness levels were used in this study [26]. The
broad-spectrum MMP inhibitor (GM6001) was purchased
from Millipore (Billerica, MA, USA).
Viral transduction and shRNA experiments
For the inhibition of RECK expression, five different spe-
cific shRNA sequences (sequentially numbered from
shRECK23 through shRECK27) were tested. These vectors
and the structural ones belonged to the Mission® shRNA
system (Sigma-Aldrich, St. Louis, MO, USA). Viral recom-
binant particles were generated by co-transfection of the
293FT virus packer cell line with these recombinant lenti-
viral vectors. Transduced cells were selected by the
addition of 2 μg/mL puromycin.
Quantitative RT-PCR studies
Total RNA was extracted from cell lines using the RNeasy
Mini Kit (Qiagen, Germantown, MD, USA). Its integrity
and quantity were evaluated using a NanoDrop™ 1000
Spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA). For cDNA synthesis, the SuperScript® III Re-
verse Transcriptase Kit was used (Life Technologies,
Carlsbad, CA, USA). Quantitative RT-PCR was carried
out using QuantiTect SYBR Green RT-PCR Kit (Qiagen).
The primers used to amplify RECK, MMP-9 and the en-
dogenous control (18S ribosomal RNA) were obtained
from a validated primer panel available from Qiagen
(QuantiTect Primer Assays). Each experiment was carried
out in duplicate. The relative expression levels were calcu-
lated according to the 2-ΔΔCt method [28].
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Western blotting
Total extracts were prepared from each cell culture line.
Equal protein amounts from each extract were fraction-
ated by SDS-PAGE and then electro-transferred to nitro-
cellulose membranes. After blockade with BSA, these
membranes were incubated with RECK (Cell Signaling)
and Lamin A/C (Santa Cruz, Santa Cruz, CA, USA)
antibodies, diluted at 1:1000 and 1:200, respectively.
Immunoreactive proteins were detected with the appro-
priate secondary horseradish peroxidase-conjugated anti-
body (GE Healthcare, Little Chalfont, UK) and visualized
using the SuperSignal West Femto Chemiluminescent
Substrate (Thermo Fisher Scientific). Quantitative densi-
tometry of the electrophoretic band images was carried
out using AlphaEaseFC software.
Gelatin zymography assays
Gelatin zymography of the conditioned media was used to
assess the in vitro enzymatic activity levels of MMP-9 in
RECK-silenced and scrambled MDA-MB-231 cells. These
samples were fractionated by 10 % SDS-polyacrylamide
gel electrophoresis co-polymerized with the enzyme sub-
strate, 0.1 % denatured type I collagen (gelatin type A;
Sigma, St. Louis, MO, USA). After electrophoresis, the
gels were washed at room temperature with 2.5 % Triton
X-100, incubated for 48 h at 37 °C in substrate buffer con-
taining 50 mM Tris buffer (pH 8.5) and 10 mM CaCl2.
Gels were stained with Coomassie Blue R-250 (Sigma) and
destained with 40 % methanol (Merck) and 10 % acetic
acid (Merck) in water. Gelatinolytic activity was visualized
as negatively staining bands. Each independent experi-
ment was performed in duplicate. Quantitative densitom-
etry of the electrophoretic band images was performed
using the AlphaEaseFC software.
In vitro invasion assays
To assess the role of RECK in cellular invasiveness
potential, RECK-deficient or scrambled control MDA-
MB-231 cells were plated on top of Matrigel-coated 8-
μm-pore transwells (BD Bioscience, Franklin Lakes, NJ,
USA). These cells were maintained in the presence of
GM6001 or its vehicle (DMSO) in serum-free medium.
The medium present in the bottom chamber was sup-
plemented with 10 % bovine serum, used as a chemo-
attractant. Cells were allowed to invade for 36 h. Cells
remaining at the top chamber were removed, and those
present at the bottom of the filter were stained and fixed
with Coomassie Blue 0.125 % in methanol:acetic acid:
H2O (45:10:45, v/v/v) for 15 min. Using the ImageJ® pro-
gram, the relative cellular invasion was quantified from
the images obtained (10× objective lens) under each
experimental condition. Non-tumorigenic S1 mam-
mary cells were used as a negative control. Triplicate
wells were utilized per condition in each independent
experiment.
Statistical analysis
Statistical analysis of data from patients was performed
using R (http://www.r-project.org/) [29]. Chi-square tests
were used to assess the association between RECK
Fig. 1 Invasive breast cancer cells express higher levels of RECK than non-invasive and non-tumorigenic ones. Western blot assays were performed to
analyze RECK protein expression levels in a panel of human breast cells. The lamin A/C protein level was used as the loading control and for
normalization. The results are presented as the means ± standard error from three independent experiments. *, p < 0.05, **, p < 0.01 and ***p < 0.001
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immunoreactivity and different clinico-pathological pa-
rameters. P-values were corrected for multiple tests by
the False Discovery Rate procedure [30]. Kaplan-Meier
(KM) plots were used for overall (OS) and disease-free
(DFS) survival analysis, and the log-rank test was used
to compare curves separated according to RECK expres-
sion. For KM analysis, 3 of 1040 subjects were identified
as being outliers by Tukey’s criterion; thus, they were re-
moved from the data analysis. Cox proportional hazards
regression was used to estimate hazard ratios (HRs).
Subjects for whom no information on the analyzed co-
variates was available, were removed, with 940 of the
1040 subjects remaining for the Cox regression analysis.
Data obtained using the cell lines model were analyzed
using the GraphPad Prism 5.0 program. In this case,
statistical significance was determined using the one way
ANOVA variance analysis and the Tukey-Kramer test.
The results were presented as the mean ± standard error
of the mean. A p-value less than 0.05 was considered to
be statistically significant.
Fig. 2 RECK functional analysis in the highly invasive MDA-MB-231 cells supports the role of RECK as an MMP inhibitor and negative modulator
of cellular invasion. a RECK mRNA and protein expression levels in the MDA-MB-231 cells infected with lentiviral particles carrying different shRNA
sequences specific for RECK inhibition (shRECK 23 through 27) or the scrambled control. The 18S ribosomal RNA expression and β-actin protein
levels were used as endogenous controls in qRT-PCR and Western blot assays, respectively. b Transwell™ invasion assays were performed to assess
the invasion capacity of scrambled control and RECK-deficient (shRECK26) cells that were treated with or without GM6001 (broad-spectrum MMP
inhibitor). c MMP-9 mRNA and protein expression (pro-enzyme and active forms) levels in control (scrambled) and RECK-silenced cells quantified
by qRT-PCR and Zymography assay, respectively. The 18S ribosomal RNA expression was used as the endogenous control in qRT-PCR assays.
Proliferation analysis of scrambled and shRECK 26 cells by (d) colony formation assays and (e) growth curves. The results are presented as the
means ± standard error from two independent experiments. **, p < 0.01 and ***, p < 0.001, all versus control (MDA-MB-231 scrambled cells)
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Results
RECK protein expression levels in human breast cells
correlates with invasiveness
In several tissue models, RECK expression was shown to
be inversely related to oncogenesis [15, 31, 32], being
expressed in normal tissues but not in many tumor cell
lines and tumor samples [15, 32]. However, in breast
cancer, the RECK expression profile remains uncertain
and controversial [24–27]. To better understand this di-
vergence, we quantified the RECK protein levels in a
panel of breast cell lines with distinct aggressiveness
levels, including non-tumorigenic (S1) cells, and non-
invasive (MCF-7 and T47D) and invasive (T4-2, MDA-
MB-231 and Hs578T) cancer cell lines (Fig. 1). We
observed that more invasive cells (T4-2, MDA-MB-231
and Hs578T) displayed significantly higher (p < 0.05, p <
0.01 and p < 0.001, respectively) RECK protein levels
than non-invasive breast cancer lineages (MCF-7 and
T47D). Furthermore, RECK protein was significantly
overexpressed in the highly invasive Hs578T cells (p <
0.001) compared with the non-malignant ones (Fig. 1).
Fig. 3 Representative immunohistochemistry images of the RECK
staining profile detected in breast tissue samples show RECK
expression in epithelial cells. a Benign proliferation, (b) ductal
carcinoma in situ (DCIS) and (c) invasive tumor samples analyzed in
tissue microarray cores
Table 1 Association between RECK expression and
clinicopathological parameters
Parameter RECK negative
no. cases (%)
RECK positive
no. cases (%)
χ2 p-value
Age
< 50 years 195 (18.8 %) 191 (18.4 %) 0.021 0.8848
≥ 50 years 324 (31.3 %) 326 (31.5 %)
Menopausal status
Premenopausal 206 (20.1 %) 197 (19.1 %) 0.082 0.7752
Postmenopausal 312 (30.4 %) 312 (30.4 %)
Tumor size
< 5 cm 252 (25.5 %) 268 (27.1 %) 1.494 0.2216
≥ 5 cm 247 (24.9 %) 223 (22.5 %)
Lymph node stage
Negative (N0) 169 (16.6 %) 160 (15.7 %) 0.243 0.6222
Positive (N1, N2, N3) 341 (33.5 %) 348 (34.2 %)
Recurrence
Negative 257 (25.1 %) 259 (25.3 %) 0.063 0.8014
Positive 258 (25.2 %) 250 (24.4 %)
ER/PR status
ER+/PR+ 208 (22.3 %) 204 (22.0 %) 8.001 0.046
ER+/PR- 125 (13.5 %) 86 (9.3 %)
ER-/PR+ 8 (0.9 %) 11 (1.2 %)
ER-/PR- 135 (14.5 %) 151 (16.3 %)
Histological grade
1 86 (8.3 %) 73 (7.1 %) 14.257 0.0008
2 315 (30.5 %) 273 (26.4 %)
3 116 (11.2 %) 170 (16.5 %)
TNM stage
1 39 (3.8 %) 17 (1.6 %) 11.069 0.0114
2A and 2B 201 (19.5 %) 204 (19.7 %)
3A, 3B, and 3C 240 (23.2 %) 240 (23.2 %)
4 39 (3.8 %) 54 (5.2 %)
χ2, Chi-square test coefficient; ER/PR, estrogen receptor/progesterone receptor
p-values considered significant after FDR correction were highlighted in bold
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Fig. 4 RECK does not a predictive value for the survival of breast cancer patients. Differences in the overall (a) and disease-free survival (b) based
on RECK immunoreactivity intensity of the diagnosed tumors were assessed using Kaplan-Meier plots
Fig. 5 RECK is not associated with the overall survival (OS) of breast cancer patients regardless of the molecular subtype examined. Kaplan-Meier
plots were obtained for OS analysis stratified by RECK expression in patients diagnosed with (a) luminal A, (b) luminal B, (c) Her2 type and
(d) basal-like breast tumors
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The doublet bands detected were possibly a result of
RECK glycosylation [33]. Therefore, our results suggest
that, unexpectedly, human breast cancer cells with a
higher invasive potential express elevated levels of RECK
(Fig. 1).
RECK down-modulates invasion and MMP-9 in highly
invasive breast cancer cells
To further clarify the specific role of RECK in mammary
neoplasia, we evaluated the functional activity of RECK.
To this end, MDA-MB-231 cells, a highly invasive human
breast cancer cell line, were used as a study model. The
RECK expression level in MDA-MB-231 cells was silenced
using different shRNA sequences (shRECK oligos num-
bered 23 through 27). Their ability to silence RECK was
confirmed by qRT-PCR and Western blot assays (Fig. 2a).
All of the sequences tested could decrease RECK expres-
sion at both the mRNA and protein levels. Subsequent
functional assays were performed using shRECK26-
transduced cells in which RECK protein expression was
reduced by 80 % relative to the scrambled control
(Fig. 2a).
First, we addressed the role of RECK in the invasion of
MDA-MB-231 cells. To this end, the in vitro invasion cap-
acities of scrambled control and RECK-downmodulated
cells were compared in Transwell™ assays (Fig. 2b). Our
results indicate that the reduction of RECK led to a signifi-
cant increase (p < 0.01) in MDA-MB-231 invasion. Treat-
ment with a broad-spectrum MMP inhibitor (GM6001)
suggests that this effect of RECK on the cell invasive cap-
acity is largely MMP dependent because GM6001 could
significantly (p < 0.01) reverse the RECK silencing effect in
MDA-MB-231 cells (Fig. 2b). Additionally, we found that
RECK-silenced cells express significantly higher levels of
both MMP-9 (p < 0.01) mRNA and its pro-enzyme (p <
0.01) than scrambled control cells (Fig. 2c). Importantly,
no influence of RECK was observed in MDA-MB-231 cell
proliferation, as indicated in Fig. 2 (d and e). These results
suggest that although its expression is correlated with in-
creased breast cancer cell aggressiveness, RECK still serves
Fig. 6 RECK is not a prognostic marker of disease-free survival (DFS) for patients diagnosed with different breast cancer molecular subtypes.
Kaplan-Meier plot estimate of DFS stratified by RECK expression in breast cancer patients diagnosed with (a) luminal A, (b) luminal B, (c) Her2 type
and (d) basal-like tumors
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as a negative regulator of cellular invasion and MMP-9 ex-
pression in MDA-MB-231 cells.
RECK expression in breast tumor tissue samples and its
association with clinico-pathological parameters
Previous reports have supported the potential role of
RECK as a molecular marker for the prognosis of several
cancer types (23). However, the association between
RECK expression and the outcome of breast cancer pa-
tients remains unclear. We evaluated RECK protein ex-
pression levels in a large series (n = 1040) of breast
cancer cases by immunohistochemistry on TMAs. The
staining pattern obtained for RECK in mammary tissue
samples derived from benign proliferation, ductal carcin-
oma in situ (DCIS) and invasive tumors is presented in
Fig. 3. In all of these distinct breast tissues, RECK was
predominantly expressed in epithelial cells, while the
stromal cells were negative.
All of the breast tumor samples included in this ana-
lysis were classified as positive or negative for RECK
considering the intensity and percentage of stained cells
(Methods). To evaluate the correlation between RECK
expression and different clinico-pathological parameters,
Chi-squared tests were performed (Table 1). Except for
histological grade (p = 0.0008) and TNM stage (p =
0.0114), there was no correlation between RECK and most
of the analyzed factors (age, menopausal status, tumor
size, lymph node stage, recurrence and ER/PR status).
RECK is not a prognostic indicator for breast cancer
patients
To determine whether RECK would be a useful marker
for the survival rate or could serve as a prognostic indica-
tor, we performed several sets of analyses. The association
between RECK and the overall (OS) and disease-free
(DFS) survival was analyzed using Kaplan-Meier curves
(Fig. 4). RECK expression did not predict any significant
differences in OS and DFS (Fig. 4) among all of the 1040
breast cancer cases analyzed.
The prognostic significance of RECK for specific co-
horts of patients was further evaluated. The tumor sam-
ples were classified according to molecular subtypes,
Fig. 7 RECK is not related to survival of breast cancer patients regardless of the lymph node status. Kaplan-Meier curves of overall (a and b) and
disease-free (c and d) survival stratified by RECK expression in breast cancer patients classified as lymph node negative (a and c) or positive
(b and d) at diagnosis
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namely luminal A, luminal B, Her2 type and basal-like/
triple negative, which, in turn, were determined by the
status of crucial breast cancer biomarkers (ER, PR and
Her2). Samples were excluded from the analysis once
the parameters required for subtype discrimination were
not available. Thus, the predictive value of RECK was
tested in 344 cases of luminal A, 19 cases of luminal B,
81 cases of Her2 type and 174 cases of Triple-negative/
basal-like breast cancer. Regardless of each molecular
subtype examined, differences in the RECK protein
levels were not associated with significant changes in OS
(Fig. 5) or DFS (Fig. 6).
The presence of tumor cells in axillary lymph nodes is
also critical for the staging and prognosis of breast can-
cer, in addition to providing a more assertive therapy
choice. Survival analyses were also performed consider-
ing two distinct groups: lymph node-negative (n = 330)
or -positive (n = 690) patients. However, independently
of lymph node status, RECK remained unable to predict
the OS and DFS of these patients (Fig. 7). Multivariate
Cox regression analysis demonstrated that RECK did not
provide independent prognostic information for breast
cancer patient survival (Tables 2 and 3), strengthening
the already reported evidence that this MMP inhibitor is
not a relevant biomarker for breast cancer.
Discussion
Since its first report, RECK down-regulation has been
linked to tumor progression [15, 32], and it is considered
to be an adequate biomarker for a better clinical course
for patients diagnosed with various tumors [23]. Never-
theless, in this study, we obtained surprising evidence
that RECK is not associated with breast cancer patient
survival. Initially, our results may seem contradictory to
previously published data. However, despite the exten-
sive amount of work addressing the RECK prognostic
Table 3 Cox regression for disease-free survival analysis in the entire patient cohort
Entire cohort (n = 940)
Univariate Multivariatea
Prognostic factor HR 95 % CI p-value HR 95 % CI p-value
RECK (low vs. high) 0.98 0.69-1.38 0.89 0.95 0.64–1.31 0.63
Age (continuous) 1.01 1.00–1.01 <0.01 1.01 1.00–1.02 <0.01
Tumor size (continuous) 1.08 1.06–1.11 <0.01 1.06 1.03–1.09 <0.01
Histological grading (3 vs. 1–2) 1.28 1.16–1.42 <0.01 1.26 1.13–1.41 <0.01
TNM stage (IV vs. I–III) 1.13 1.05–1.22 <0.01 1.07 0.99–1.14 0.08
Nodal status (positive vs. negative) 1.57 1.37–1.80 <0.01 1.51 1.31–1.74 <0.01
ER (positive vs. negative) 0.89 0.78–1.02 0.11 1.04 0.87–1.23 0.68
PR (positive vs. negative) 0.85 0.75–0.97 0.01 0.92 0.79–1.08 0.3
Her2 (positive vs. negative) 1.16 0.96–1.40 0.13 0.96 0.78–1.18 0.71
RECK. REversion-inducing Cysteine-rich protein with Kazal motifs; ER. estrogen receptor; PR. progesterone receptor; Her2. human epidermal growth factor 2
aAdjusted for all other variables in the table
Table 2 Cox regression for overall survival analysis in the entire patient cohort
Entire cohort (n = 940)
Univariate Multivariatea
Prognostic factor HR 95 % CI p-value HR 95 % CI p-value
RECK (low vs. high) 0.95 0.67–1.37 0.8 0.91 0.63–1.31 0.63
Age (continuous) 1.01 1.01–1.02 <0.01 1.01 1.01–1.02 <0.01
Tumor size (continuous) 1.05 1.02–1.07 <0.01 1.03 1.01–1.06 0.02
Histological grading (3 vs. 1–2) 1.27 1.14–1.40 <0.01 1.24 1.11–1.38 <0.01
TNM stage (IV vs. I–III) 1.05 0.98–1.13 0.15 1 0.93–1.07 0.96
Nodal status (positive vs. negative) 1.53 1.34–1.76 <0.01 1.51 1.32–1.74 <0.01
ER (positive vs. negative) 0.88 0.77–1.01 0.08 0.96 0.81–1.13 0.6
PR (positive vs. negative) 0.88 0.77–1.00 0.05 0.96 0.82–1.12 0.59
Her2 (positive vs. negative) 1.22 1.01–1.48 0.04 1.01 0.82–1.25 0.91
RECK. REversion-inducing Cysteine-rich protein with Kazal motifs; ER. estrogen receptor; PR. progesterone receptor; Her2. human epidermal growth factor 2
aAdjusted for all other variables in the table
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value for prostate, lung and pancreatic tumors, RECK
function and expression profile in breast cancer remain
an open question. The few preceding papers on human
mammary gland assessed RECK in a reduced number of
samples and, in most cases, only at the transcriptional
level [24–27]. Moreover, these prior studies are contro-
versial. Some of them corroborate the typical RECK
down-modulation as a hallmark of tumor aggressiveness
[24, 25]. Conversely, another report demonstrated not
only higher RECK levels in invasive breast cancer cell
lines than in the non-invasive one but also a positive
correlation between RECK and MMP expression in
tumor tissue samples [26]. In the present work, we mea-
sured RECK protein levels both in a panel of human
breast cell lines and in a large series (1040) of breast
cancer cases, allowing a more significant conclusion.
Additionally, we performed a functional analysis of
RECK in a breast cancer cell model. Despite the differ-
ential expression profile displayed by RECK in breast
cancer samples, we confirmed that it performs similar
functions in MDA-MB-231 cells to those previously de-
scribed in other models. In this cell culture model,
RECK continues to act as an invasion inhibitor via
MMP down-modulation even in highly invasive human
breast cancer cells. Although, at first, it may seem con-
flicting, we hypothesize that, to restore the balance be-
tween proteases and their inhibitors, cells respond by
inducing RECK. In fact, an increase in both MMPs and
TIMPs has been described as a central and crucial hall-
mark of tumor progression. Although this may be a
mechanism to maintain the protease/inhibitor ratio in
balance, this cellular response mechanism cannot block
disease progression.
Conclusions
In contrast to other tumor types, RECK expression can-
not predict breast cancer patient survival, although its
inhibitory function in invasion has been confirmed. Des-
pite the well-known cancer heterogeneity, several studies
are still aiming to identify a universal tumor marker and
draw an overall conclusion. However, in agreement with
the emerging concept of personalized cancer therapy,
general conclusions should be avoided, and more tumor-
specific biomarkers should be sought.
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